Shengli Oil Field Central Hospital

Jinan, China

Shengli Oil Field Central Hospital

Jinan, China
SEARCH FILTERS
Time filter
Source Type

Ding H.,Shengli Oil field Central Hospital | Zhang H.,Qingdao University | Li D.,Shandong University | Yi X.,Shengli Oil field Central Hospital | And 4 more authors.
Cellular and Molecular Immunology | Year: 2017

Hypoxic-ischemic brain damage (HIBD) is a common cause of infant death. The purpose of our research was to explore the immunoregulatory mechanism of placenta-derived mesenchymal stem cells (PD-MSCs) in HIBD treatment. Seven-day-old rat pups were randomly divided into HIBD, PD-MSC, fibroblast, and control groups. Forty-eight hours after HIBD induction, cells at a density of 5 × 104 cells/10 μl were injected into the cerebral tissue in the PD-MSC and fibroblast groups. The TNF-α, interleukin- 17 (IL-17), interferon-γ (IFN-γ), and IL-10 levels were detected through quantitative real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). Regulatory T cell (Tregs) populations were detected through flow cytometry, and forkhead box P3 (Foxp3) was measured through western blot analysis. Behavioral tests and gross and pathological examinations showed that PD-MSC treatment exerted significantly stronger neuroprotective effects than the other treatments. The expression levels of pro-inflammatory cytokines were substantially upregulated after HI injury. Compared with fibroblast treatment, PD-MSC treatment inhibited the production of pro-inflammatory cytokines and increased the production of IL-10 in the ischemic hemispheres and peripheral blood serum (all P < 0.01). Flow cytometry results showed a notable increase in the number of Tregs within the spleen of the HIBD group. Moreover, the number of Tregs and the Foxp3 expression levels were higher in the PD-MSC treatment group than in the HIBD and fibroblast groups (all P < 0.01). Our research suggests that the mechanism of PD-MSC treatment for HIBD partially involves inflammatory response suppression. © 2017 CSI and USTC All rights reserved.


Niu P.,Chinese National Institute for Viral Disease Control and Prevention | Qi S.,Chinese National Institute for Viral Disease Control and Prevention | Yu B.,Shengli Oil Field Central Hospital | Zhang C.,Chinese National Institute for Viral Disease Control and Prevention | And 3 more authors.
Archives of Virology | Year: 2016

Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease (HFMD). A commercial TaqMan probe-based real-time PCR assay has been widely used for the differential detection of EV71 despite its relatively high cost and failure to detect samples with a low viral load (Ct value > 35). In this study, a highly sensitive real-time nested RT-PCR (RTN RT-PCR) assay in a single closed tube for detection of EV71 in HFMD was developed. The sensitivity and specificity of this assay were evaluated using a reference EV71 stock and a panel of controls consisting of coxsackievirus A16 (CVA16) and common respiratory viruses, respectively. The clinical performance of this assay was evaluated and compared with those of a commercial TaqMan probe-based real-time PCR (qRT-PCR) assay and a traditional two-step nested RT-PCR assay. The limit of detection for the RTN RT-PCR assay was 0.01 TCID50/ml, with a Ct value of 38.3, which was the same as that of the traditional two-step nested RT-PCR assay and approximately tenfold lower than that of the qRT-PCR assay. When testing the reference strain EV71, this assay showed favorable detection reproducibility and no obvious cross-reactivity. The testing results of 100 clinical throat swabs from HFMD-suspected patients revealed that 41 samples were positive for EV71 by both RTN RT-PCR and traditional two-step nested RT-PCR assays, whereas only 29 were EV71 positive by qRT-PCR assay. © 2016, Springer-Verlag Wien.


Li F.-H.,Sun Yat Sen University | Li F.-H.,Shengli Oil Field Central Hospital | Shen L.,Peking University | Li Z.-H.,Sun Yat Sen University | And 5 more authors.
World Journal of Gastroenterology | Year: 2010

Aim: To investigate the prognostic value of KRAS mutation, and phosphatase and tensin (PTEN) expression in Chinese metastatic colorectal cancer metastatic colorectal cancer (mCRC) patients treated with cetuximab. Methods: Ninety Chinese mCRC patients treated with cetuximab were evaluated for KRAS mutation and PTEN protein expression by DNA sequencing of codons 12 and 13 and immunohistochemistry, respectively. We then selected 61 patients treated with cetuximab, either in combination with chemotherapy, or alone as a second-line or third-line regimen to assess whether KRAS mutation or PTEN protein expression is associated with the response and the survival time of mCRC patients treated with cetuximab. Results: KRAS mutation was found in 30 (33.3%) tumor samples from the 90 patients, and positive PTEN expression was detected in 58 (64.4%) of the 90 patients. Among the 61 patients who were treated with cetuximab as a second-line or third-line regimen, the resistance to cetuximab was found in 22 patients with KRAS mutation and in 39 patients without KRAS mutation, with a response rate of 4.5% and 46.1% respectively (P = 0.001), a shorter median progression-free survival (PFS) time of 14 ± 1.3 wk and 32 ± 2.5 wk respectively (P < 0.001), a median overall survival (OS) time of 11 ± 1.2 mo and 19 ± 1.8 mo respectively (P < 0.001), as well as in 24 patients with negative PTEN expression and in 37 patients with positive PTEN expression respectively (P < 0.001), with a responsive rate of 4.2% and 48.6% respectively, a shorter median PFS survival time of 17 ± 2.0 wk and 28 ± 1.9 wk respectively (P = 0.07), and a median OS time of 11 ± 1.3 mo and 18 ± 1.9 mo respectively (P = 0.004). Combined KRAS mutation and PTEN expression analysis showed that the PFS and OS time of patients with two favorable prognostic factors were longer than those of patients with one favorable prognostic factor or no favorable prognostic factor (P < 0.001). Conclusion: KRAS mutation and PTEN protein expression are significantly correlated with the response rate and survival time of Chinese mCRC patients treated with cetuximab. © 2010 Baishideng.


Chen Q.,Shengli Oil Field Central Hospital | Xiao J.,Shandong University | Zhang P.,Tianjin Entry Exit Inspection and Quarantine Bureau | Chen L.,U.S. Center for Disease Control and Prevention | And 2 more authors.
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi | Year: 2016

OBJECTIVE: To investigate the association between serum direct bilirubin (DBIL) with metabolic syndrome (MS) and its components.METHODS: A dynamic health check-up cohort study was set up from 2006 to 2011. 5 258 participants who satisfied the two basic rules: 1) being free of MS at the 1(st) health check-up program; 2) having at least two intact health checks were included in this study. With generalized estimating equation (GEE) model, after adjusting for items as age, gender, smoking, drinking, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, uric acid, blood urea nitrogen and white blood cells, the multivariable relative risks (RRs) of DBIL with MS and their components were analyzed.RESULTS: The RRs of DBIL for MS was 0.722 (95%CI: 0.654-0.797), which showing a dose-response. Serum DBIL was negatively associated with obesity and hyperlipidemia. Taking factors as gender and age into account, in the <45 years and 45-55 years groups, the RRs of DBIL for MS in females appeared as 0.516 (95%CI: 0.349-0.761) and 0.435 (95%CI: 0.256-0.740). And in males of <45 years and 45-55 years, the RRs of DBIL for MS were 0.738 (95% CI: 0.644-0.846) and 0.790 (95% CI:0.667-0.937), respectively.CONCLUSIONS: The elevated DBIL levels in serum appeared an early biomarker for MS and its components (obesity and hyperlipidemia). In particular,they may play a role in reducing the risk of MS in both females and males before 55 years of age.


Cui L.-H.,Qingdao University | Quan Z.-Y.,Yanbian University | Piao J.-M.,Qingdao University | Zhang T.-T.,Qingdao University | And 4 more authors.
International Journal of Molecular Sciences | Year: 2016

Folate and vitamin B12 involved in the one-carbon metabolism may play a key role in carcinogenesis and progression of hepatocellular carcinoma (HCC) through influencing DNA integrity. The purpose of this study is to evaluate the association of plasma folate and vitamin B12 levels with HCC in a case-control study on 312 HCC patients and 325 cancer-free controls. Plasma concentrations of folate and vitamin B12 in all the subjects were measured by electrochemiluminescence immunoassay. Meanwhile, the information of HCC patients’ clinical characteristics including tumor-node-metastasis (TNM) stage, tumor size and tumor markers were collected. The patients of HCC had significantly lower folate levels than those of controls; there was no significant difference in the mean of plasma vitamin B12 levels. We also observed an inverse association between the levels of plasma folate and HCC: the adjusted odds ratios (OR) (95% confidence intervals (CI)) of HCC from the highest to lowest quartile of folate were 0.30 (0.15-0.60), 0.33 (0.17-0.65), and 0.19 (0.09-0.38). Compared to the subjects in the lowest quartile of plasma vitamin B12, only the subjects in the highest quartile of vitamin B12 exhibited a significant positive relationship with HCC, the adjusted OR was 2.01 (95% CI, 1.02-3.98). HCC patients with Stage III and IV or bigger tumor size had lower folate and higher vitamin B12 levels. There was no significant difference in the mean plasma folate levels of the HCC cases in tumor markers status (AFP, CEA and CA19-9 levels), whereas patients with higher CEA or CA19-9 levels retained significantly more plasma vitamin B12 than those with normal-CEA or CA19-9 level. In conclusion, plasma folate and vitamin B12 levels could be associated with HCC, and might be used as predictors of clinical characteristics of HCC patients. However, further prospective studies are essential to confirm the observed results. © 2016 by the authors; licensee MDPI, Basel, Switzerland.


PubMed | Centers for Disease Control and Prevention, Tianjin Entry Exit Inspection and Quarantine Bureau, Shandong University and Shengli Oil Field Central Hospital
Type: Journal Article | Journal: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi | Year: 2016

To investigate the association between serum direct bilirubin (DBIL) with metabolic syndrome (MS) and its components.A dynamic health check-up cohort study was set up from 2006 to 2011. 5 258 participants who satisfied the two basic rules: 1) being free of MS at the 1(st) health check-up program; 2) having at least two intact health checks were included in this study. With generalized estimating equation (GEE) model, after adjusting for items as age, gender, smoking, drinking, alanine aminotransferase, aspartate aminotransferase, -glutamyltransferase, uric acid, blood urea nitrogen and white blood cells, the multivariable relative risks (RRs) of DBIL with MS and their components were analyzed.The RRs of DBIL for MS was 0.722 (95%CI: 0.654-0.797), which showing a dose-response. Serum DBIL was negatively associated with obesity and hyperlipidemia. Taking factors as gender and age into account, in the <45 years and 45-55 years groups, the RRs of DBIL for MS in females appeared as 0.516 (95%CI: 0.349-0.761) and 0.435 (95%CI: 0.256-0.740). And in males of <45 years and 45-55 years, the RRs of DBIL for MS were 0.738 (95% CI: 0.644-0.846) and 0.790 (95% CI:0.667-0.937), respectively.The elevated DBIL levels in serum appeared an early biomarker for MS and its components (obesity and hyperlipidemia). In particular,they may play a role in reducing the risk of MS in both females and males before 55 years of age.


Ding H.-F.,Shengli Oil Field Central Hospital | Zhang H.,Qingdao Municipal Hospital | Ding H.-F.,Shandong University | Li D.,Shandong University | And 4 more authors.
World Journal of Pediatrics | Year: 2014

Background: Oxidative stress is involved in the development of hypoxic-ischemic brain damage (HIBD). In this study, we investigated the therapeutic effects of placenta-derived mesenchymal stem cells (PD-MSCs) and explored the NF-E2-related factor-2/heme oxygenase-1 (Nrf2/HO-1) signaling pathway in treating HIBD.Methods: P7 rats were subjected to hypoxic-ischemic brain injury and randomly divided into four groups (control, HIBD, HIBD+PD-MSCs, and HIBD+fibroblasts). Forty-eight hours after the induction of HIBD, 5×105 of PD-MSCs were injected into cerebral tissue in the HIBD+PD-MSCs group, while the same dose of fibroblasts were injected in the HIBD+fibroblasts group. Morris Water Maze, gross and pathological changes were tested at P28. The level of malondialdehyde (MDA) was detected in rats’ hippocampus. RT-PCR and western blot analysis were used to evaluate the changes of Nrf2/HO-1.Results: The HIBD group showed significantly longer escape latency and a lower frequency of original platform crossing in the Morris Water Maze compared with the control group. Rats receiving PD-MSCs showed significant improvement of HIBD. The pathological changes were evident after HIBD, but ameliorated in the PD-MSCs group. Compared with the control group, HO-1 and Nrf2 were up-regulated at gene and protein levels in the HI brain, beginning at 6 hours and peaking at 48 hours (P<0.05). The expression of HO-1 and Nrf2 in the PD-MSCs treatment group was more pronounced than in the HIBD group (P<0.01). PD-MSCs also decreased MDA production in the brain tissue.Conclusion: These results demonstrate that PD-MSCs have neuroprotective effect during the treatment of HIBD and that the mechanism may be partly due to alleviating oxidative stress. © 2014, Children's Hospital, Zhejiang University School of Medicine and Springer-Verlag Berlin Heidelberg.


Han X.,Tianjin Medical University | Han X.,Shengli Oil Field Central Hospital | Jiang K.,Tianjin Medical University | Wang B.,Tianjin Medical University | And 3 more authors.
Clinical Drug Investigation | Year: 2015

Background and Objective: Chronic gastritis frequently progresses into precancerous intestinal metaplasia and intraepithelial neoplasia lesions. Rebamipide is a free radical scavenger and we assessed its efficacy on clinical symptoms, gastric mucosal lesions, pathologic grade, and immunohistochemistry in chronic gastritis patients. Methods: 178 eligible patients were randomized into treatment and control groups. Both groups followed an optimized lifestyle for 26 weeks, but the treatment group was additionally medicated with rebamipide 0.1 g three times per day. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by the Modified Lanza Scoring (MLS) and histological changes were evaluated by the Updated Sydney System Score (USSS). Gastric mucosa immunohistochemistry in the treatment group was performed using the intestinal metaplasia markers caudal type homeobox transcription factor 2 (CDX2) and trefoil factor 3 (TFF3) detection. Results: There were significant outcome differences between the treatment and control groups regarding the clinical symptom scores (2.62 ± 1.86 vs. 1.55 ± 1.61, P = 0.0001), gastric mucosal lesion scores (0.57 ± 1.05 vs. 0.16 ± 0.90, P = 0.002), and inflammation (P < 0.05). Only in the treated patients were the rates of intestinal metaplasia (P = 0.017 vs. P = 0.123) and low-grade intraepithelial neoplasia (P = 0.005 vs. P = 0.226) significantly reduced after 26 weeks. The percentages of CDX2 (31.5 vs. 15.7 %, P = 0.021) and TFF3 (44.9 vs. 25.8 %, P = 0.012) expressing gastric mucosa cells were significantly lower after rebamipide medication than pre-treatment values. Conclusions: Rebamipide improved the clinical symptoms, gastric mucosal lesions, and pathological grades of chronic gastritis patients and decreased the expression rates of CDX2 and TFF3 in gastric cells. © 2015, Springer International Publishing Switzerland.


PubMed | Qingdao University, Shandong University and Shengli Oil field Central Hospital
Type: | Journal: Cellular & molecular immunology | Year: 2015

Hypoxic-ischemic brain damage (HIBD) is a common cause of infant death. The purpose of our research was to explore the immunoregulatory mechanism of placenta-derived mesenchymal stem cells (PD-MSCs) in HIBD treatment. Seven-day-old rat pups were randomly divided into HIBD, PD-MSC, fibroblast, and control groups. Forty-eight hours after HIBD induction, cells at a density of 5 104 cells/10 l were injected into the cerebral tissue in the PD-MSC and fibroblast groups. The TNF-, interleukin- 17 (IL-17), interferon- (IFN-), and IL-10 levels were detected through quantitative real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). Regulatory T cell (Tregs) populations were detected through flow cytometry, and forkhead box P3 (Foxp3) was measured through western blot analysis. Behavioral tests and gross and pathological examinations showed that PD-MSC treatment exerted significantly stronger neuroprotective effects than the other treatments. The expression levels of pro-inflammatory cytokines were substantially upregulated after HI injury. Compared with fibroblast treatment, PD-MSC treatment inhibited the production of pro-inflammatory cytokines and increased the production of IL-10 in the ischemic hemispheres and peripheral blood serum (all P < 0.01). Flow cytometry results showed a notable increase in the number of Tregs within the spleen of the HIBD group. Moreover, the number of Tregs and the Foxp3 expression levels were higher in the PD-MSC treatment group than in the HIBD and fibroblast groups (all P < 0.01). Our research suggests that the mechanism of PD-MSC treatment for HIBD partially involves inflammatory response suppression.Cellular & Molecular Immunology advance online publication, 28 December 2015; doi:10.1038/cmi.2015.99.


PubMed | Chinese National Institute for Viral Disease Control and Prevention and Shengli Oil Field Central Hospital
Type: Journal Article | Journal: Archives of virology | Year: 2016

Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease (HFMD). A commercial TaqMan probe-based real-time PCR assay has been widely used for the differential detection of EV71 despite its relatively high cost and failure to detect samples with a low viral load (Ct value>35). In this study, a highly sensitive real-time nested RT-PCR (RTN RT-PCR) assay in a single closed tube for detection of EV71 in HFMD was developed. The sensitivity and specificity of this assay were evaluated using a reference EV71 stock and a panel of controls consisting of coxsackievirus A16 (CVA16) and common respiratory viruses, respectively. The clinical performance of this assay was evaluated and compared with those of a commercial TaqMan probe-based real-time PCR (qRT-PCR) assay and a traditional two-step nested RT-PCR assay. The limit of detection for the RTN RT-PCR assay was 0.01TCID50/ml, with a Ct value of 38.3, which was the same as that of the traditional two-step nested RT-PCR assay and approximately tenfold lower than that of the qRT-PCR assay. When testing the reference strain EV71, this assay showed favorable detection reproducibility and no obvious cross-reactivity. The testing results of 100 clinical throat swabs from HFMD-suspected patients revealed that 41 samples were positive for EV71 by both RTN RT-PCR and traditional two-step nested RT-PCR assays, whereas only 29 were EV71 positive by qRT-PCR assay.

Loading Shengli Oil Field Central Hospital collaborators
Loading Shengli Oil Field Central Hospital collaborators